$INVA News

Innoviva Inc (NASDAQ:INVA): A Decent Value Stock With an Undervalued Earnings Profile

Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026

Do Options Traders Know Something About Innoviva Stock We Don't?

Is Innoviva (INVA) Undervalued As Zacks Flags Its Value Appeal?

INVA vs. MRK: Which Stock Is the Better Value Option?

Should Value Investors Buy Innoviva (INVA) Stock?

Innoviva (NASDAQ:INVA) Fits the Affordable Growth Mold

Oppenheimer Assumes Innoviva at Outperform, Announces Price Target of $35

Innoviva (NASDAQ:INVA): An Undervalued Value Stock Backed by Strong Cash Flow

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

How Innoviva’s Q2 Loss and Aggressive Buybacks Could Reshape Capital Allocation for INVA Investors

Cantor Fitzgerald Maintains Overweight on Innoviva, Lowers Price Target to $34

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Innoviva Q2 EPS $(1.14) Misses $0.40 Estimate, Sales $119.600M Beat $110.985M Estimate

Innoviva (INVA): Affordable Growth Stock at a Reasonable Valuation

Innoviva Inc (NASDAQ:INVA): A Decent Value Play with Strong Fundamentals

Is Innoviva (INVA) One of the Best Cheap Small Cap Stocks to Buy Now?

INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout